Sofusa anti-PD1

Sofusa anti-PD1 is our product candidate for the treatment of Cutaneous T-Cell Lymphoma

  • CTCL is a rare form of T-cell lymphoma affecting the skin. It develops when T-cells become abnormal. T-cells are white blood cells that fight infection
  • There is currently no clearly identified cause of CTCL.  It is not contagious
  • CTCL generally affects older people (40 – 60 years). Twice more prevalent among male v. female patients
  • It is estimated that there are about 20,000 people with this condition and over 3,000 new cases each year in US
  • The 3-year survival rates of low risk, low-intermediate risk, intermediate-high risk, and high risk groups were 60%, 30%, 10%, and 0%, respectively. Current treatment for T-cell NHL patients, especially the high risk patients, cannot achieve satisfactory outcomes (nih.gov)
  • Lymphatic delivery of anti-PD-1 treatment has potential to improve response rates and reduce treatment related adverse events